We describe our use of a liver allograft from a donor who died of intracran
ial hemorrhage after brodifacoum ingestion. Because brodifacoum can remain
in the human body for months, the recipient's posttransplantation coagulati
on profiles and serum brodifacoum levels were monitored closely. Her posttr
ansplantation course was excellent, with no coagulation problem. At 15 mont
hs posttransplantation, she is well, with normal liver function and coagula
tion profile. We conclude that brodifacoum toxicity is not a strict contrai
ndication to liver donation. Copyright (C) 1999 by the American Association
for the Study of Liver Diseases.